PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Friday, March 22, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update. EventAgile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference ...

PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX) ("Agile" or the "Company"), a women's healthcare company, today announced that it has paid-off the remainder of its debt facility with Perceptive Advisors ("Perceptive"). This significant milestone completes the repayment schedule contemplated by the Loan Agreement between the Company and Perceptive, which originated in 2020 and ended as of March 11, 2024. The Company remains focused on growing Twirla® and advancing t ...

New York, United States, March 12, 2024 (GLOBE NEWSWIRE) -- Contraception encompasses the use of drugs to prevent pregnancy, the transmission of sexually transmitted diseases (STDs), the transmission of sexually transmitted infections (STIs), family planning, and birth control. The use of contraceptive drugs and emergency contraceptives, especially among adolescents, and an increase in awareness of sexually transmitted infections (STIs) are the primary factors driving the expansion of the global contracepti ...

Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022   GAAP Operating Expenses for Full Year 2023 Expected to be in the Range of $30 to $31.5 Million, a Decrease of 47% to 44% Compared to Full Year 2022 PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc ...

Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women These Actions Follow Several Months of Activity by the Biden Administration to Strengthen Access to All FDA Approved Contraceptives as Defined in President Biden's June 2023 Executive Order The Company Commends the Administration for their Continued Commitment to Reproductive Health PRINCETON, N.J., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a wo ...

Agile Therapeutics, Inc. (OTCQB:AGRX) Q3 2023 Earnings Call November 9, 2023 8:30 AM ET Company Participants Matt Riley - Head of Investor Relations Alfred Altomari - Chairman and Chief Executive Officer Scott Coiante - Chief Financial Officer Amy Welsh - Chief Commercial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Naz Rahman - Maxim Group Operator Good morning, and welcome to the Agile Therapeutics Third Quarter 2023 Financial Results Conference Call. Please note, today's event is be ...

Agile Therapeutics Third Quarter 2023 Earnings Call November 9, 2023 NASDAQ: AGRX 1 Forward-Looking Statements Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases, use terms such as "predicts," "believes," "potential, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other jurisdiction ...

Agile Therapeutics Second Quarter 2023 Earnings Call August 9, 2023 NASDAQ: AGRX 1 Forward-Looking Statements Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases, use terms such as "predicts," "believes," "potential," ...

Start Time: 08:30 January 1, 0000 9:06 AM ET Agile Therapeutics, Inc. (OTCQB:AGRX) Q2 2023 Earnings Conference Call August 09, 2023, 08:30 AM ET Company Participants Al Altomari - Chairman and CEO Scott Coiante - CFO Amy Welsh - Chief Commercial Officer Matt Riley - Head, IR Conference Call Participants Oren Livnat - H.C. Wainwright Operator Good morning, and welcome to the Agile Therapeutics Second Quarter of 2023 Financial Results Conference Call. Please note today’s event is being recorded. I would now l ...